In receptor pharmacology, retatrutide serves as the reference balanced tri-agonist
Each compound has a distinct profile of benefits, drawbacks, and clinical data depth
Network meta-analyses suggest that higher-dose semaglutide (1 mg and 2 mg weekly) and tirzepatide (a dual GIP/GLP-1 receptor agonist) demonstrate superior A1c reductions compared to other agents in the class, with mean reductions of 1.52.0% or greater from baseline
May your starting dose stay smooth, your titration stay steady, and your results stay lasting.
Then, after the second month, theyll reassess and potentially increase to 1 mg, then 2 mg after another month if necessary
Retatrutide is a triple agonist, meaning it simultaneously activates three receptor types that single-target drugs like semaglutide do not touch